🔬The BioAI Phase Shift - Matthew McPartlon & Neil Patil, Chai Discovery

Latent Space · 2 months ago · 5

Chai Discovery, an OpenAI-backed AI x pharma tool provider, closed multiple pharma “tools” deals around the JPM Pharma conference and its Science team released a podcast with cofounders Matt McPartlon and Neil Patil on what changed. The article cites that Chai Discovery is worth $4B and reports that since June it announced three major additional deals with Lilly, Novartis, and argenx plus an expansion of its Eli Lilly program. It argues that improved structural-to-binding modeling quality has made AI-driven molecule design “good enough to trust,” enabling teams to scale discovery faster and shift iteration toward engineering-style optimization rather than relying on extensive lab trial-and-error.